Mareb

Olmesartan medoxomil, the active ingredient in Mareb, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is combined with amlodipine, a calcium channel blocker, to treat hypertension in adult patients. GNH USA supplies Mareb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mareb is an antihypertensive combination that targets high blood pressure through dual mechanisms. - Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - Stage 2 hypertension: provides additional blood‑pressure reduction when monotherapy is insufficient. - Uncontrolled hypertension on monotherapy: offers combined action to achieve target blood pressure.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness: especially after the first dose. - Flushing: transient warmth and redness. - Fatigue: general tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or throat requiring urgent care. - Severe hypotension: markedly low blood pressure causing faintness. - Hepatic dysfunction: abnormal liver enzymes. - Renal impairment: worsening kidney function. - Cardiac arrhythmia: irregular heartbeat. - Allergic rash: widespread skin reaction.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal function: assess creatinine clearance in patients with kidney disease. - Hepatic disease: use caution in moderate to severe liver impairment. - Electrolyte balance: monitor potassium and sodium levels. - Pregnancy: avoid use unless clearly needed; discuss risks with a healthcare professional. - Elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mareb may interact with other medicines that affect blood pressure or electrolyte balance.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockers (e.g., ACE inhibitors, other ARBs): risk of hyperkalaemia and renal dysfunction. - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - NSAIDs: can reduce antihypertensive efficacy and affect renal function. - Lithium: may increase lithium concentrations. - St. John's wort: may reduce amlodipine exposure. - Antacids containing aluminum/magnesium: may affect absorption of olmesartan.